|
1
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
|
|
3
|
Moreau JE, Anderson K, Mauney JR, Nguyen
T, Kaplan DL and Rosenblatt M: Tissue-engineered bone serves as a
target for metastasis of human breast cancer in a mouse model.
Cancer Res. 67:10304–10308. 2007. View Article : Google Scholar
|
|
4
|
Fagan-Solis KD, Schneider SS, Pentecost
BT, Bentley BA, Otis CN, Gierthy JF and Arcaro KF: The RhoA pathway
mediates MMP-2 and MMP-9-independent invasive behavior in a
triple-negative breast cancer cell line. J Cell Biochem.
114:1385–1394. 2013. View Article : Google Scholar
|
|
5
|
Malmgren JA, Mayer M, Atwood MK and Kaplan
HG: Differential presentation and survival of de novo and recurrent
metastatic breast cancer over time: 1990–2010. Breast Cancer Res
Treat. 167:579–590. 2018. View Article : Google Scholar
|
|
6
|
Fan J, Deng X, Gallagher JW, Huang H,
Huang Y, Wen J, Ferrari M, Shen H and Hu Y: Monitoring the
progression of metastatic breast cancer on nanoporous silica chips.
Philos Trans- Royal Soc, Math Phys Eng Sci. 370:2433–2447.
2012.
|
|
7
|
Bottino J, Gelaleti GB, Maschio LB,
Jardim-Perassi BV and de Campos Zuccari DA: Immunoexpression of
ROCK-1 and MMP-9 as prognostic markers in breast cancer. Acta
Histochem. 116:1367–1373. 2014. View Article : Google Scholar
|
|
8
|
Olayide A, Samuel O, Ganiyu R, Moses A,
Gafar O, Abiola D, Dapo K and John A: How effective is the
treatment of locally advanced and metastatic breast cancer in
developing centres?: A retrospective review. Ethiop J Health Sci.
25:337–344. 2015. View Article : Google Scholar
|
|
9
|
Scorilas A, Karameris A, Arnogiannaki N,
Ardavanis A, Bassilopoulos P, Trangas T and Talieri M:
Overexpression of matrix-metalloproteinase-9 in human breast
cancer: A potential favourable indicator in node-negative patients.
Br J Cancer. 84:1488–1496. 2001. View Article : Google Scholar
|
|
10
|
Fidler IJ: Metastasis: Quantitative
analysis of distribution and fate of tumor emboli labeled with 125
I-5-iodo-2-deoxyuridine. J Natl Cancer Inst. 45:773–782. 1970.
|
|
11
|
Lambert AW, Pattabiraman DR and Weinberg
RA: Emerging biological principles of metastasis. Cell.
168:670–691. 2017. View Article : Google Scholar
|
|
12
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: From dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar
|
|
13
|
Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo
CC, Chu PY, Hung YM, Chou SW, Yang YY, Chang GC, et al: Surface
α-enolase promotes extracellular matrix degradation and tumor
metastasis and represents a new therapeutic target. PLoS One.
8:e693542013. View Article : Google Scholar
|
|
14
|
Wang X, Lu H, Urvalek AM, Li T, Yu L,
Lamar J, DiPersio CM, Feustel PJ and Zhao J: KLF8 promotes human
breast cancer cell invasion and metastasis by transcriptional
activation of MMP9. Oncogene. 30:1901–1911. 2011. View Article : Google Scholar
|
|
15
|
Ortíz-López L, Morales-Mulia S,
Ramírez-Rodríguez G and Benítez-King G: ROCK-regulated cytoskeletal
dynamics participate in the inhibitory effect of melatonin on
cancer cell migration. J Pineal Res. 46:15–21. 2009. View Article : Google Scholar
|
|
16
|
Paolillo M and Schinelli S: Extracellular
matrix alterations in metastatic processes. Int J Mol Sci.
20:49472019. View Article : Google Scholar
|
|
17
|
Castro-Castro A, Marchesin V, Monteiro P,
Lodillinsky C, Rossé C and Chavrier P: Cellular and molecular
mechanisms of MT1-MMP-dependent cancer cell invasion. Annu Rev Cell
Dev Biol. 32:555–576. 2016. View Article : Google Scholar
|
|
18
|
Shay G, Lynch CC and Fingleton B: Moving
targets: Emerging roles for MMPs in cancer progression and
metastasis. Matrix Biol. 44-46:200–206. 2015. View Article : Google Scholar
|
|
19
|
Gonzalez-Avila G, Sommer B, Mendoza-Posada
DA, Ramos C, Garcia-Hernandez AA and Falfan-Valencia R: Matrix
metalloproteinases participation in the metastatic process and
their diagnostic and therapeutic applications in cancer. Crit Rev
Oncol Hematol. 137:57–83. 2019. View Article : Google Scholar
|
|
20
|
Yousef EM, Tahir MR, St-Pierre Y and
Gaboury LA: MMP-9 expression varies according to molecular subtypes
of breast cancer. BMC Cancer. 14:6092014. View Article : Google Scholar
|
|
21
|
Stuelten CH, DaCosta Byfield S, Arany PR,
Karpova TS, Stetler-Stevenson WG and Roberts AB: Breast cancer
cells induce stromal fibroblasts to express MMP-9 via secretion of
TNF-alpha and TGF-beta. J Cell Sci. 118:2143–2153. 2005. View Article : Google Scholar
|
|
22
|
Sand JM, Larsen L, Hogaboam C, Martinez F,
Han M, Larsen MR, Nawrocki A, Zheng Q, Karsdal MA and Leeming DJ:
MMP mediated degradation of type IV collagen alpha 1 and alpha 3
chains reflects basement membrane remodeling in experimental and
clinical fibrosis - validation of two novel biomarker assays. PLoS
One. 8:e849342013. View Article : Google Scholar
|
|
23
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar
|
|
24
|
Owyong M, Chou J, van den Bijgaart RJ,
Kong N, Efe G, Maynard C, Talmi-Frank D, Solomonov I, Koopman C,
Hadler-Olsen E, et al: MMP9 modulates the metastatic cascade and
immune landscape for breast cancer anti-metastatic therapy. Life
Sci Alliance. 2:e2018002262019. View Article : Google Scholar
|
|
25
|
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS,
Di GH, Liu G, Li FM, Ou ZL, et al: Prognostic value of matrix
metalloproteinases (MMP-2 and MMP-9) in patients with lymph
node-negative breast carcinoma. Breast Cancer Res Treat. 88:75–85.
2004. View Article : Google Scholar
|
|
26
|
Vizoso FJ, González LO, Corte MD,
Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM and
García-Muñiz JL: Study of matrix metalloproteinases and their
inhibitors in breast cancer. Br J Cancer. 96:903–911. 2007.
View Article : Google Scholar
|
|
27
|
Darlix A, Lamy PJ, Lopez-Crapez E,
Braccini AL, Firmin N, Romieu G, Thézenas S and Jacot W: Serum NSE,
MMP-9 and HER2 extracellular domain are associated with brain
metastases in metastatic breast cancer patients: Predictive
biomarkers for brain metastases? Int J Cancer. 139:2299–2311. 2016.
View Article : Google Scholar
|
|
28
|
Ranogajec I, Jakić-Razumović J, Puzović V
and Gabrilovac J: Prognostic value of matrix metalloproteinase-2
(MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase
N/CD13 in breast cancer patients. Med Oncol. 29:561–569. 2012.
View Article : Google Scholar
|
|
29
|
Li H, Qiu Z, Li F and Wang C: The
relationship between MMP-2 and MMP-9 expression levels with breast
cancer incidence and prognosis. Oncol Lett. 14:5865–5870. 2017.
|
|
30
|
Dhar M, Lam JN, Walser T, Dubinett SM,
Rettig MB and Di Carlo D: Functional profiling of circulating tumor
cells with an integrated vortex capture and single-cell protease
activity assay. Proc Natl Acad Sci USA. 115:9986–9991. 2018.
View Article : Google Scholar
|
|
31
|
Cierna Z, Mego M, Janega P, Karaba M,
Minarik G, Benca J, Sedlácková T, Cingelova S, Gronesova P,
Manasova D, et al: Matrix metalloproteinase 1 and circulating tumor
cells in early breast cancer. BMC Cancer. 14:4722014. View Article : Google Scholar
|
|
32
|
Cardoso F, Kyriakides S, Ohno S,
Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S and Senkus E;
ESMO Guidelines Committee, : Early breast cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 30:16742019. View Article : Google Scholar
|
|
33
|
Allison KH, Brogi E and Ellis IO: WHO
Classification of Tumours Editorial Board. Breast Tumours. 5th
edition. IARC Press; Lyon: 2019
|
|
34
|
van Nes JG, de Kruijf EM, Putter H,
Faratian D, Munro A, Campbell F, Smit VT, Liefers GJ, Kuppen PJ,
van de Velde CJ, et al: Co-expression of SNAIL and TWIST determines
prognosis in estrogen receptor-positive early breast cancer
patients. Breast Cancer Res Treat. 133:49–59. 2012. View Article : Google Scholar
|
|
35
|
Chovanec M, Cierna Z, Miskovska V,
Machalekova K, Svetlovska D, Kalavska K, Rejlekova K, Spanik S,
Kajo K, Babal P, et al: Prognostic role of programmed-death ligand
1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular
germ cell tumors. Oncotarget. 8:21794–21805. 2017. View Article : Google Scholar
|
|
36
|
Chovanec M, Cierna Z, Miskovska V,
Machalekova K, Kalavska K, Rejlekova K, Svetlovska D, Macak D,
Spanik S, Kajo K, et al: β-catenin is a marker of poor clinical
characteristics and suppressed immune infiltration in testicular
germ cell tumors. BMC Cancer. 18:10622018. View Article : Google Scholar
|
|
37
|
Mego M, Karaba M, Minarik G, Benca J,
Sedlácková T, Tothova L, Vlkova B, Cierna Z, Janega P, Luha J, et
al: Relationship between circulating tumor cells, blood
coagulation, and urokinase-plasminogen-activator system in early
breast cancer patients. Breast J. 21:155–160. 2015. View Article : Google Scholar
|
|
38
|
Mego M, Karaba M, Minarik G, Benca J,
Silvia J, Sedlackova T, Manasova D, Kalavska K, Pindak D,
Cristofanilli M, et al: Circulating tumor cells with
epithelial-to-mesenchymal transition phenotypes associated with
inferior outcomes in primary breast cancer. Anticancer Res.
39:1829–1837. 2019. View Article : Google Scholar
|
|
39
|
Mego M, Mani SA, Lee BN, Li C, Evans KW,
Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, et al:
Expression of epithelial-mesenchymal transition-inducing
transcription factors in primary breast cancer: The effect of
neoadjuvant therapy. Int J Cancer. 130:808–816. 2012. View Article : Google Scholar
|
|
40
|
Yadav L, Puri N, Rastogi V, Satpute P,
Ahmad R and Kaur G: Matrix metalloproteinases and cancer - roles in
threat and therapy. Asian Pac J Cancer Prev. 15:1085–1091. 2014.
View Article : Google Scholar
|
|
41
|
Westermarck J and Kähäri VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999. View Article : Google Scholar
|
|
42
|
Alaseem A, Alhazzani K, Dondapati P,
Alobid S, Bishayee A and Rathinavelu A: Matrix metalloproteinases:
A challenging paradigm of cancer management. Semin Cancer Biol.
56:100–115. 2019. View Article : Google Scholar
|
|
43
|
González LO, Pidal I, Junquera S, Corte
MD, Vázquez J, Rodríguez JC, Lamelas ML, Merino AM, García-Muñiz JL
and Vizoso FJ: Overexpression of matrix metalloproteinases and
their inhibitors in mononuclear inflammatory cells in breast cancer
correlates with metastasis-relapse. Br J Cancer. 97:957–963. 2007.
View Article : Google Scholar
|
|
44
|
Radisky ES, Raeeszadeh-Sarmazdeh M and
Radisky DC: Therapeutic Potential of Matrix Metalloproteinase
Inhibition in Breast Cancer. J Cell Biochem. 118:3531–3548. 2017.
View Article : Google Scholar
|
|
45
|
Song J, Su H, Zhou YY and Guo LL:
Prognostic value of matrix metalloproteinase 9 expression in breast
cancer patients: A meta-analysis. Asian Pac J Cancer Prev.
14:1615–1621. 2013. View Article : Google Scholar
|
|
46
|
Ren F, Tang R, Zhang X, Madushi WM, Luo D,
Dang Y, Li Z, Wei K and Chen G: Overexpression of MMP family
members functions as prognostic biomarker for breast cancer
patients: A systematic review and meta-analysis. PLoS One.
10:e01355442015. View Article : Google Scholar
|
|
47
|
Pellikainen JM, Ropponen KM, Kataja VV,
Kellokoski JK, Eskelinen MJ and Kosma VM: Expression of matrix
metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special
reference to activator protein-2, HER2, and prognosis. Clin Cancer
Res. 10:7621–7628. 2004. View Article : Google Scholar
|
|
48
|
González LO, Corte MD, Junquera S,
González-Fernández R, del Casar JM, García C, Andicoechea A,
Vázquez J, Pérez-Fernández R and Vizoso FJ: Expression and
prognostic significance of metalloproteases and their inhibitors in
luminal A and basal-like phenotypes of breast carcinoma. Hum
Pathol. 40:1224–1233. 2009. View Article : Google Scholar
|
|
49
|
Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu
S, Zhang X, Liu Y, Song Y, Liu L, et al: High expression of CD147
and MMP-9 is correlated with poor prognosis of triple-negative
breast cancer (TNBC) patients. Med Oncol. 30:3352013. View Article : Google Scholar
|
|
50
|
Yang J, Min KW, Kim DH, Son BK, Moon KM,
Wi YC, Bang SS, Oh YH, Do SI, Chae SW, et al: High TNFRSF12A level
associated with MMP-9 overexpression is linked to poor prognosis in
breast cancer: Gene set enrichment analysis and validation in
large-scale cohorts. PLoS One. 13:e02021132018. View Article : Google Scholar
|
|
51
|
Radisky ES and Radisky DC: Matrix
metalloproteinase-induced epithelial-mesenchymal transition in
breast cancer. J Mammary Gland Biol Neoplasia. 15:201–212. 2010.
View Article : Google Scholar
|
|
52
|
Foroni C, Broggini M, Generali D and Damia
G: Epithelial-mesenchymal transition and breast cancer: Role,
molecular mechanisms and clinical impact. Cancer Treat Rev.
38:689–697. 2012. View Article : Google Scholar
|
|
53
|
Li W, Li S, Deng L, Yang S, Li M, Long S,
Chen S, Lin F and Xiao L: Decreased MT1-MMP in gastric cancer
suppressed cell migration and invasion via regulating MMPs and EMT.
Tumour Biol. 36:6883–6889. 2015. View Article : Google Scholar
|
|
54
|
Zhong Y, Lu YT, Sun Y, Shi ZH, Li NG, Tang
YP and Duan JA: Recent opportunities in matrix metalloproteinase
inhibitor drug design for cancer. Expert Opin Drug Discov.
13:75–87. 2018. View Article : Google Scholar
|
|
55
|
Arkadash V, Yosef G, Shirian J, Cohen I,
Horev Y, Grossman M, Sagi I, Radisky ES, Shifman JM and Papo N:
Development of high affinity and high specificity inhibitors of
matrix metalloproteinase 14 through computational design and
directed evolution. J Biol Chem. 292:3481–3495. 2017. View Article : Google Scholar
|
|
56
|
Winer A, Adams S and Mignatti P: Matrix
metalloproteinase inhibitors in cancer therapy: Turning past
failures intofuture successes. Mol Cancer Ther. 17:1147–1155. 2018.
View Article : Google Scholar
|
|
57
|
Pozzi A, LeVine WF and Gardner HA: Low
plasma levels of matrix metalloproteinase 9 permit increased tumor
angiogenesis. Oncogene. 21:272–281. 2002. View Article : Google Scholar
|
|
58
|
Montel V, Kleeman J, Agarwal D, Spinella
D, Kawai K and Tarin D: Altered metastatic behavior of human breast
cancer cells after experimental manipulation of matrix
metalloproteinase 8 gene expression. Cancer Res. 64:1687–1694.
2004. View Article : Google Scholar
|
|
59
|
Decock J, Hendrickx W, Thirkettle S,
Gutiérrez-Fernández A, Robinson SD and Edwards DR: Pleiotropic
functions of the tumor- and metastasis-suppressing matrix
metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice.
Breast Cancer Res. 17:382015. View Article : Google Scholar
|
|
60
|
Juurikka K, Butler GS, Salo T, Nyberg P
and Åström P: The role of MMP8 in cancer: A systematic review. Int
J Mol Sci. 20:45062019. View Article : Google Scholar
|
